In this review:
Minimal residual disease after ASCT
Cytogenetic abnormalities in AL amyloidosis
Stratifying risk in smouldering MM
Ultra-high-risk myeloma and plasma cell leukaemia treatment
Iberdomide combination treatments for relapsed/refractory MM
Ciltacabtagene autoleucel CAR T-cell therapy for progressive MM
Monoallelic deletion of BCMA locus in MM
Talquetamab in relapsed/refractory MM
Melflufen vs pomalidomide in relapsed/refractory MM
Relapsed/refractory MM after BCMA-targeted CAR-T therapy
Please login below to download this issue (PDF)